Fundraising Fox
Melior Discovery
2 known investors
Find your way into Melior Discovery
Sign up to see every warm intro you have to Melior Discovery
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Melior Discovery team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Melior Discovery provides in vivo pharmacology services and phenotypic screening platforms for pharmaceutical and biopharmaceutical companies to evaluate candidate therapeutics in animal disease models. The company operates proprietary technology including theraTRACE® to identify new therapeutic potential and support drug development and repositioning.
Founders & leadership
AR
Andrew ReaumePresident and CEO, Co-FounderAndrew Reaume is co-founder and president/CEO of Melior Discovery, which provides in vivo pharmacology services and phenotypic screening platforms for drug discovery and development. He has more than 20 years of experience in pharmaceutical research, including roles at multinational pharma companies and biotech firms.
AR
Andrew Reaume, PhD, MBAPresident and CEO, Co-Founder
Investors · 2
Also in the syndicate · 1
Osage Partners
In the news
Frequently asked questions
- What does Melior Discovery do?
- Melior Discovery provides in vivo pharmacology services and phenotypic screening platforms for pharmaceutical and biopharmaceutical companies to evaluate candidate therapeutics in animal disease models. The company operates proprietary technology including theraTRACE® to identify new therapeutic potential and support drug development and repositioning.
- Who founded Melior Discovery?
- Melior Discovery was founded by Andrew Reaume, Andrew Reaume, PhD, MBA.
- Who are Melior Discovery's investors?
- Melior Discovery's investors include BioAdvance.